In Reply We thank Vander for his insightful comments on our study of pentosan polysulfate (PPS) maculopathy.1 We agree with the general sentiment, particularly with the statements regarding the seriousness of this public health issue and the importance of being careful in drawing conclusions from the data. As Vander suggested, our report on disease course after drug cessation has clinical and medicolegal ramifications. More importantly, affected patients eagerly await information about long-term visual prognosis, and we wish to provide them with accurate information.
Shah R, Jain N. Long-term Macular Effects of Pentosan Polysulfate Sodium Exposure Uncertain—Let’s Not Jump to Conclusions—Reply. JAMA Ophthalmol. 2021;139(3):364–365. doi:10.1001/jamaophthalmol.2020.6618
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.